## HIMS: Hims & Hers Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.8% below STRENGTH zone (4.0-10.0%); PEG 1.88 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($33.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.14M) |
| Sells | 20 ($2.40M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 67.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.2% (+1198.1%)
- Blackrock Inc.: 11.5% (+1.6%)
- Vanguard Group Inc: 8.9% (+4.5%)
- Capital World Invest: 8.6% (+1.2%)
- Farallon Capital Man: 4.9% (+30.8%)

### Key Risks

1. High beta (2.41) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. High short interest (35.2%, 3.9 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.9% below SMA200.

### Catalysts

- Momentum building: MRS_20 improving +5.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.88 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 26%). Insider selling cluster ($2.4M in 90 days), potential headwind. Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.8B |
| Beta | 2.41 |
| 52W Range | $23.97 - $72.98 |
| Short Interest | 35.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.88 |
| Forward P/E | 59.5 |
| Current P/E | 82.1 |
| YoY Growth | 37.8% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -3.8% to 1.8% (+5.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 4.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (0.81), confirming momentum. RSI neutral at 48. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.81% (CS: 67) | Neutral |
| RSI_14 | 47.5 | Neutral |
| MACD Histogram | 0.81 | Bullish |
| vs SMA20 | 1.041x | Above |
| vs SMA50 | 0.850x | Below |
| vs SMA200 | 0.851x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $39.20
- **Stop Loss:** $33.88 (13.6% risk)
- **Target:** $44.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $3,645.60
- **Portfolio %:** 3.65%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-23 (Est: $0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.10 | $0.06 | -41.0% |
| 2025Q2 | $0.16 | $0.17 | +3.2% |
| 2025Q1 | $0.12 | $0.20 | +65.0% |
| 2024Q4 | $0.11 | $0.11 | +0.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*